Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 3Completed 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 7Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Ovarian Neoplasms 5Melanoma 5Carcinoma, Renal Cell 5Skin Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma 4Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Mouth Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 3Adenocarcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2

Interventions

Bevacizumab 77Fluorouracil 55Cetuximab 48Oxaliplatin 43Leucovorin 42pembrolizumab 37Irinotecan 33Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 19trifluridine tipiracil drug combination 17Panitumumab 15Blood Specimen Collection 15Nivolumab 14Magnetic Resonance Spectroscopy 14regorafenib 13Biopsy 13Trifluridine 12Gemcitabine 12Cisplatin 12Standard of Care 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 10Cyclophosphamide 9tislelizumab 8Trastuzumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × cemiplimab × Clear all
NCT07147231 2026-05-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
86 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06205836 2026-05-06

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
44 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡